These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M
2936 results:

  • 1. Detection of idh mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry.
    Shahi M; Pringle S; Morris M; Garcia DM; Quiñones-Hinojosa A; Cooks RG
    Sci Rep; 2024 Nov; 14(1):26865. PubMed ID: 39500924
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. NF1 expression profiling in idh-wildtype glioblastoma: genomic associations and survival outcomes.
    Chang M; Sherief M; Ioannou M; Chinnasamy V; Chen L; Frost M; Mattson-Hoss M; Sarnoff H; Kamson DO; Holdhoff M; Mukherjee D; Bettegowda C; Rincon-Torroella J; Croog V; Huang P; Rodriguez FJ; Lucas CG; Schreck KC
    Acta Neuropathol Commun; 2024 Oct; 12(1):172. PubMed ID: 39472976
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The apparent diffusion coefficient can serve as a predictor of survival in patients with gliomas.
    Jiang X; Xu XN; Yuan XY; Jiang HR; Zhao MJ; Duan YX; Li G
    Radiat Oncol; 2024 Oct; 19(1):149. PubMed ID: 39472956
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Functional and oncological outcomes following more than three consecutive surgical resections for multiple relapses of initially grade 2 idh-mutated gliomas.
    Nassihi A; Duffau H
    Acta Neurochir (Wien); 2024 Oct; 166(1):425. PubMed ID: 39465448
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Association of Schimmelpenning Syndrome with Astrocytoma (WHO Grade 3): Case Report.
    Tumova A; Auslands K; Millers A; Priede Z; Buks M; Ozola A; Ozoliņa E; Bicāns K; Ulmanis R
    Medicina (Kaunas); 2024 Oct; 60(10):. PubMed ID: 39459475
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Optic Nerve Glioblastoma with Optic Chiasm Involvement: A Case Report and a Brief Literature Review.
    Brokāns A; Dolgopolova J; Saulītis A; Spulle U; Rancāns K; Meiers D; Hasnere S; Balodis A
    Medicina (Kaunas); 2024 Oct; 60(10):. PubMed ID: 39459474
    [No Abstract]    [Full Text] [Related]  

  • 7. Dual phenotypes in recurrent astrocytoma, idh-mutant; coexistence of idh-mutant and idh-wildtype components: a case report with genetic and epigenetic analysis.
    Yamaguchi J; Ohka F; Seki M; Motomura K; Deguchi S; Shiba Y; Okumura Y; Kibe Y; Shimizu H; Maeda S; Takido Y; Yamamoto R; Nakamura A; Karube K; Saito R
    Acta Neuropathol Commun; 2024 Oct; 12(1):169. PubMed ID: 39456052
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Machine learning-based new classification for immune infiltration of gliomas.
    Yuan F; Wang Y; Yuan L; Ye L; Hu Y; Cheng H; Li Y
    PLoS One; 2024; 19(10):e0312071. PubMed ID: 39453922
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Health-Related Quality of Life and Treatment Satisfaction of Patients with Malignant idh Wild-Type Gliomas and Their Caregivers.
    Fischl A; Gerken M; Lindberg-Scharf P; Haedenkamp TM; Rosengarth K; Hillberg A; Vogelhuber M; Schön I; Proescholdt M; Araceli T; Koller M; Herrmann A; Kölbl O; Pukrop T; Riemenschneider MJ; Schmidt NO; Klinkhammer-Schalke M; Linker R; Hau P; Bumes E
    Curr Oncol; 2024 Oct; 31(10):6155-6170. PubMed ID: 39451763
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Macrophage polarization-related gene signature for risk stratification and prognosis of survival in gliomas.
    Zhong W; Xiong K; Li S; Li C
    J Cell Mol Med; 2024 Oct; 28(20):e70000. PubMed ID: 39448550
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Recent updates in pediatric diffuse glioma classification: insights and conclusions from the WHO 5
    Patel T; Singh G; Goswami P
    J Med Life; 2024 Jul; 17(7):665-670. PubMed ID: 39440342
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [PET/CT with 11C-methionine as a predictor of disease-free survival in patients with idh1 wild type diffuse glioma].
    Skvortsova TY; Savintseva ZI; Gurchin AF; Seliverstov RY
    Zh Vopr Neirokhir Im N N Burdenko; 2024; 88(5):6-13. PubMed ID: 39422678
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A DTI-based radiomics model for predicting epidermal growth factor receptor (EGFR) amplification in adult idh1-wild glioblastomas.
    Wang D; Han Q; Yang S; Cui J; Xia W; Lu Y; Yin B; Geng D
    Acta Radiol; 2024 Oct; 65(10):1291-1299. PubMed ID: 39411882
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of idh-mutated gliomas.
    Zang Y; Feng L; Zheng F; Shi X; Chen X
    Clin Neurol Neurosurg; 2024 Nov; 246():108579. PubMed ID: 39395280
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Ultra-early stage lower-grade gliomas: How can we define and differentiate these easily misdiagnosed gliomas through intraoperative molecular diagnosis.
    Han Z; Wang Q; Li J; Chi H; Ma C; Jia D; Qi M; Li X; Zhang K; Feng Z; Xue H; Li G
    CNS Neurosci Ther; 2024 Oct; 30(10):e70044. PubMed ID: 39385311
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in idh-mutant astrocytoma.
    Ghisai SA; van Hijfte L; Vallentgoed WR; Tesileanu CMS; de Heer I; Kros JM; Sanson M; Gorlia T; Wick W; Vogelbaum MA; Brandes AA; Franceschi E; Clement PM; Nowak AK; Golfinopoulos V; van den Bent MJ; French PJ; Hoogstrate Y
    Acta Neuropathol; 2024 Oct; 148(1):50. PubMed ID: 39382765
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Comment on, "T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, idh-mutant".
    Chellapandian H; Jeyachandran S
    Neurosurg Rev; 2024 Oct; 47(1):742. PubMed ID: 39377853
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. N-Acetyl-L-Cysteine (NAC) Blunts Axitinib-Related Adverse Effects in Preclinical Models of Glioblastoma.
    Formato A; Salbini M; Orecchini E; Pellegrini M; Buccarelli M; Vitiani LR; Giannetti S; Pallini R; D'Alessandris QG; Lauretti L; Martini M; De Falco V; Levi A; Falchetti ML; Mongiardi MP
    Cancer Med; 2024 Oct; 13(19):e70279. PubMed ID: 39377544
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Vorasidenib: First Approval.
    Lamb YN
    Drugs; 2024 Oct; 84(10):1325-1331. PubMed ID: 39375303
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review.
    Jiwei B; Abulimiti M; Yonglong J; Jie W; Shuyan Z; Chao L; Zishen W; Wei W; Yinuo L; Weiwei W; Lu Y; Shimizu S
    Radiat Oncol; 2024 Oct; 19(1):136. PubMed ID: 39369243
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 147.